Monopoly v. Openness: Two sides of IP coin in the pharmaceutical industry

Olga Gurgula

Research output: Contribution to journalArticlepeer-review


The pharmaceutical industry extensively relies on the patent system. It actively lobbies for the strengthening of patent protection of its medical products and the results of its efforts may be found in the majority of bilateral and multilateral agreements, including the TRIPS and the most recent TPPA, augmented by private patent strategies pursued by pharmaceutical companies. However, some recent developments show the emerging tendency of implementing different business models by pharmaceutical companies that may mark the beginning of transformation of this industry. Among these developments is an ‘open innovation’ model, which has increasingly been followed by some research
institutions and pharmaceutical companies aiming at facilitating the creation of new and affordable medicines, as well as providing transparency in order to enhance safety and efficacy of drugs. This article will discuss these two current developments in the pharmaceutical industry, i.e. strong IP protection against open innovation.
Original languageEnglish
Pages (from-to)206-220
JournalThe Journal of World Intellectual Property
Issue number5-6
Publication statusPublished - 28 Sept 2017

Bibliographical note

© 2017 The Authors. The Journal of World Intellectual Property © 2017 John Wiley & Sons Ltd. This is the peer reviewed version of the following article, which has been published in final form at This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.


  • patents; the pharmaceutical industry; access to medicines; open innovation.


Dive into the research topics of 'Monopoly v. Openness: Two sides of IP coin in the pharmaceutical industry'. Together they form a unique fingerprint.

Cite this